Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy
Cancer Cell, ISSN: 1535-6108, Vol: 39, Issue: 11, Page: 1455-1457
2021
- 4Citations
- 19Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- Captures19
- Readers19
- 19
Article Description
EGFR oncogenic mutations predict sensitivity to EGFR inhibitors in NSCLC, but less is known about EGFR “variants of unknown significance.” Using preclinical models, 3D structure analyses, and patient response data, Robichaux et al. show in Nature that mutations in structural regions of EGFR predict responses to different EGFR inhibitors.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1535610821005638; http://dx.doi.org/10.1016/j.ccell.2021.10.012; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85121710719&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/34752753; https://linkinghub.elsevier.com/retrieve/pii/S1535610821005638; https://dx.doi.org/10.1016/j.ccell.2021.10.012
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know